VIDEO: Avacincaptad pegol demonstrates positive results at 24 months

ByYasha Modi, MD

ByCory Perla

Fact checked byChristine Klimanskis, ELS

In this video, Yasha S. Modi, MD, discusses the 2-year results of the GATHER2 trial, which showed that avacincaptad pegol had a positive effect on geographic atrophy reduction.

The data, presented at the American Academy of Ophthalmology meeting, indicated that patients treated with avacincaptad pegol every other month did as well with progression rate as patients treated every month, Modi said.

“This was not a prespecified endpoint, and I think we need to understand a little bit more about that data,” Modi, associate professor, department of ophthalmology at NYU Grossman School of Medicine, said. “We got some really topline data from an excellent presenter, Arshad Khanani, and it would be really good to see that data in a little bit more detail.”

Reference:

Khanani A. GATHER2: Two-year data. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Modi reports consulting for AbbVie/Allergan, Alcon, Apellis, Astellas, Bausch + Lomb, DORC, EyePoint, Genentech, Regeneron, Thea and Zeiss.

Take Homes in Age-related Macular Degeneration

Read more

VIDEO: Avacincaptad pegol demonstrates positive results at 24 months

Reference:

Related Content